MYC and acute myeloid leukemia: MYC phosphorylation, ubiquitination and proteasome degradation has been extensively studied to gain control of MYC levels in cancer cells, with several compounds in preclinical development or early clinical trials11,13,43, including all-trans retinoic acid (ATRA) and Vismodegib, which are approved by the FDA for the treatment of acute myeloid leukemia and basal-cell carcinoma44,45.